Recommendations for the use of biologic (TNF-α blocking) agents in the treatment of rheumatoid arthritis in Italy

被引：0

作者：

Valesini, G.

Montecucco, C.

Cutolo, M.

机构：

[1] Univ Roma La Sapienza, Cattedra Reumatol, Rome, Italy

[2] Univ Pavia, I-27100 Pavia, Italy

[3] Univ Genoa, Genoa, Italy

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2006年 / 24卷 / 04期

关键词：

rheumatoid arthritis; anti-TNF; biological agents; management; recommendations;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The present report is devoted to drawing up and disseminating specific recommendations for the use of anti-TNF-alpha therapies in patients with rheumatoid arthritis (RA) in Italy. The document reports and discusses the published literature concerning the criteria for inclusion, assessment of response and for withdrawal of treatment with TNF blocking agents in RA. Several specific points concerning more sensitive warnings are discussed: tuberculosis, hepatitis, lymphoma, and cardiovascular risk and induction of autoimmunity. The recommendations are summarized in an 8-point table approved by the executive committee of the Italian Society for Rheumatology.

引用

页码：413 / 423

页数：11

共 110 条

[21] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].